Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1055722 | 0.78 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL536979 | 0.72 | DPP4 (0.33) | — | |
| SCHEMBL7452627 | 0.62 | CDK2 (0.32) | — | |
| SCHEMBL6322394 | 0.61 | DCPS (0.30) | — | |
| SCHEMBL29233039 | 0.60 | MEN1 (0.33) | — | |
| SCHEMBL142922 | 0.60 | QTRT1 (0.42) | CDK1 | |
| SCHEMBL1025894 | 0.59 | CCNA2 (0.37) | — | |
| SCHEMBL8010167 | 0.58 | — | — | |
| SCHEMBL6323165 | 0.58 | DPP4 (0.32) | — | |
| SCHEMBL7938941 | 0.58 | CDK1 (0.45) | CSNK1A1CLK4KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 215 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814407-B2 | Multiple coupling and oxidation method | ROCHE INNOVATION CENTER COPENHAGEN A/S (CH) | 2023-11-14 | — | — | US | claimed |
| US-20230340008-A1 | BRIDGED NUCLEOSIDE AND NUCLEOTIDE USING SAME | JAPAN AS REPRESENTED BY DIRECTOR GENERAL OF NATIONAL INSTITUTE OF HEALTH SCIENCES (JP) | 2023-10-26 | — | — | US | claimed |
| WO-2023167094-A1 | 5'-MODIFIED NUCLEOSIDE AND NUCLEOTIDE USING SAME | 国立大学法人大阪大学 | 2023-09-07 | — | — | WO | claimed |
| US-20230124641-A1 | CROSS-LINKED NUCLEOSIDE AND NUCLEOTIDE USING SAME | JAPAN AS REPRESENTED BY DIRECTOR GENERAL OF NATIONAL INSTITUTE OF HEALTH SCIENCES (JP) | 2023-04-20 | — | — | US | claimed |
| EP-4108262-A1 | CROSS-LINKED NUCLEOSIDE AND NUCLEOTIDE USING SAME | OSAKA UNIVERSITY (JP) | 2022-12-28 | — | — | EP | claimed |
| EP-4108670-A1 | BRIDGED NUCLEOSIDE AND NUCLEOTIDE USING SAME | OSAKA UNIVERSITY (JP) | 2022-12-28 | — | — | EP | claimed |
| CN-115135658-A | Bridged nucleoside and nucleotide using the same | 国立大学法人大阪大学 | 2022-09-30 | — | — | CN | claimed |
| US-20220127300-A1 | 5'-MODIFIED NUCLEOSIDE AND NUCLEOTIDE USING SAME | OSAKA UNIVERSITY (JP) | 2022-04-28 | — | — | US | claimed |
| WO-2022004388-A1 | 5'-MODIFIED NUCLEOSIDE AND NUCLEOTIDE USING SAME | 国立大学法人大阪大学 | 2022-01-06 | — | — | WO | claimed |
| EP-3925965-A1 | 5'-MODIFIED NUCLEOSIDE AND NUCLEOTIDE USING SAME | Osaka University (JP) | 2021-12-22 | — | — | EP | claimed |
| EP-1152009-B1 | NOVEL NUCLEOSIDES AND OLIGONUCLEOTIDE ANALOGUES | SANKYO CO (JP) | 2005-01-26 | — | — | EP | claimed |
| EP-1486504-A1 | NUCLEOSIDE ANALOGUES WHOSE SUGAR MOIETIES ARE BOUND IN S-FORM AND OLIGONUCLEOTIDE DERIVATIVES COMPRISING NUCLEOTIDE ANALOGUES THEREOF | Imanishi, Takeshi (JP) | 2004-12-15 | — | — | EP | claimed |
| EP-1481983-A1 | NUCLEOSIDE ANALOGUES AND OLIGONUCLEOTIDE DERIVATIVE COMPRISING NUCLEOTIDE ANALOGUE THEREOF | Imanishi, Takeshi (JP) | 2004-12-01 | — | — | EP | claimed |
| EP-1201678-B1 | NOVEL BICYCLONUCLEOSIDE ANALOGUES | SANKYO CO (JP) | 2004-09-22 | — | — | EP | claimed |
| US-20040143114-A1 | Novel bicyclonucleoside analogues | SANKYO COMPANY, LIMITED (JP) | 2004-07-22 | — | — | US | claimed |
| US-20030207841-A1 | Novel nucleoside and oligonucleotide analogues | SANKYO COMPANY LIMITED (JP) | 2003-11-06 | — | — | US | claimed |
| US-RE38090-E1 | Antitumor activity; useful for treatment and prevention of cancers | Matsuda, Akira (JP) | 2003-04-22 | — | — | US | claimed |
| US-20020147332-A1 | Novel nucleoside and oligonucleotide analogues | SANKYO COMPANY, LIMITED (JP) | 2002-10-10 | — | — | US | claimed |
| EP-1201678-A1 | NOVEL BICYCLONUCLEOSIDE ANALOGUES | Sankyo Company, Limited (JP) | 2002-05-02 | — | — | EP | claimed |
| EP-1152009-A1 | NOVEL NUCLEOSIDES AND OLIGONUCLEOTIDE ANALOGUES | Sankyo Company, Limited (JP) | 2001-11-07 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147332-A1 | Novel nucleoside and oligonucleotide analogues | RNGTT, NSUN2, MTAP | CSNK1A1 685/4885CLK4 4788/4885KDM4E 2870/4885 |
| US-20230340008-A1 | BRIDGED NUCLEOSIDE AND NUCLEOTIDE USING SAME | SLC29A1, SLC29A2, PNP | CSNK1A1 3539/4885CLK4 3169/4885KDM4E 4101/4885 |
| US-20030207841-A1 | Novel nucleoside and oligonucleotide analogues | RNGTT, NSUN2, MTAP | CSNK1A1 685/4885CLK4 4788/4885KDM4E 2870/4885 |
| US-11814407-B2 | Multiple coupling and oxidation method | RNGTT, PCNA, TYMP | CSNK1A1 2087/4885CLK4 2156/4885KDM4E 2834/4885 |
| US-20230124641-A1 | CROSS-LINKED NUCLEOSIDE AND NUCLEOTIDE USING SAME | RNGTT, NUDT1, SLC29A2 | CSNK1A1 3426/4885CLK4 1424/4885KDM4E 4157/4885 |
| US-20040143114-A1 | Novel bicyclonucleoside analogues | PURB, DUT, NSUN2 | CSNK1A1 1887/4885CLK4 4637/4885KDM4E 3088/4885 |
| US-20220127300-A1 | 5'-MODIFIED NUCLEOSIDE AND NUCLEOTIDE USING SAME | NT5C3B, DUT, RNGTT | CSNK1A1 3002/4885CLK4 3777/4885KDM4E 3019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.